Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Evgen Pharma ( (GB:TCF) ) is now available.
TheraCryf plc has rejected a conditional, non-binding proposal to acquire its lead neuropsychiatry assets, including its Orexin-1 and dopamine transporter programmes, after the board unanimously decided the offer undervalued their current and future commercial potential. The decision underscores the company’s confidence in these assets, particularly its fully funded Orexin-1 addiction programme, which it views as a significant long-term value driver in a large and growing treatment market.
Management highlighted strong progress toward first-in-human studies of the Orexin-1 candidate, with data generation funded through to a planned Phase 1 application by the fourth quarter of 2026. The board framed the rejection as a strategic move to capture more upside from advancing its pipeline internally, pointing to rising deal activity and high valuations for orexin-system modulators as supportive context for its stance on preserving shareholder value.
Spark’s Take on TCF Stock
According to Spark, TipRanks’ AI Analyst, TCF is a Neutral.
The score is held down primarily by weak fundamentals—ongoing losses, inconsistent revenue, and persistent cash burn—despite recent improvement and a debt-free balance sheet. Technicals are supportive with the price above key moving averages, but overbought RSI reduces the technical score. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
To see Spark’s full report on TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a UK-based biotechnology company focused on developing new medicines for addiction and other neuropsychiatric disorders, key areas of unmet need within central nervous system diseases. Its lead asset is a novel, best-in-class Orexin-1 receptor antagonist for addiction, supported by a capital-light, virtual development model aimed at advancing programmes to early clinical or proof-of-concept stages before partnering. The company also develops a dopamine transporter modulator for brain-related fatigue and maintains a legacy oncology programme in glioblastoma.
Average Trading Volume: 3,728,686
Technical Sentiment Signal: Strong Sell
Current Market Cap: £4.19M
Learn more about TCF stock on TipRanks’ Stock Analysis page.